Corcept Therapeutics (CORT) Cash & Current Investments (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Cash & Current Investments data on file, last reported at $338.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 4.78% year-over-year to $338.2 million; the trailing twelve-month figure through Mar 2026 stood at $338.2 million (up 4.78% YoY), and the FY2025 full-year result was $372.2 million, down 2.92% from the prior year.
• Cash & Current Investments retreated to $338.2 million in Q1 2026, from $372.2 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $473.2 million in Q2 2024 to a low of $322.8 million in Q1 2025.
• A 5-year average of $384.7 million and a median of $372.2 million in 2025 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments surged 93.11% in 2022 and slipped 27.67% in 2025, its largest moves.
• Tracing CORT's Cash & Current Investments over 5 years: stood at $431.7 million in 2022, then dropped by 14.7% to $368.2 million in 2023, then gained by 4.1% to $383.3 million in 2024, then declined by 2.92% to $372.2 million in 2025, then declined by 9.13% to $338.2 million in 2026.
• Business Quant data shows CORT's Cash & Current Investments at $338.2 million in Q1 2026, $372.2 million in Q4 2025, and $421.7 million in Q3 2025.